AZN.UK

11,376

+1.61%↑

HLN.UK

395

+2.12%↑

INDV

736

-1.27%↓

AZN.UK

11,376

+1.61%↑

HLN.UK

395

+2.12%↑

INDV

736

-1.27%↓

AZN.UK

11,376

+1.61%↑

HLN.UK

395

+2.12%↑

INDV

736

-1.27%↓

AZN.UK

11,376

+1.61%↑

HLN.UK

395

+2.12%↑

INDV

736

-1.27%↓

AZN.UK

11,376

+1.61%↑

HLN.UK

395

+2.12%↑

INDV

736

-1.27%↓

Search

GlaxoSmithKline PLC

Chiusa

SettoreSettore sanitario

1,460 2.13

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1429

Massimo

1485.5

Metriche Chiave

By Trading Economics

Entrata

559M

501M

Vendite

105M

8.1B

P/E

Media del settore

23.581

63.778

EPS

0.232

Rendimento da dividendi

4.3

Margine di Profitto

6.172

Dipendenti

68,629

EBITDA

-52M

1.1B

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+11.15% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

4.30%

2.39%

Utili prossimi

30 apr 2025

Prossima data del Dividendo

10 apr 2025

Prossima data del' Ex Dividendo

15 mag 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-586M

59B

Apertura precedente

1457.87

Chiusura precedente

1460

Notizie sul Sentiment di mercato

By Acuity

38%

62%

139 / 386 Classifica in Healthcare

GlaxoSmithKline PLC Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 feb 2025, 11:32 UTC

Utili

GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook -- 2nd Update

5 feb 2025, 08:56 UTC

Utili

Correction to GSK Article

5 feb 2025, 08:24 UTC

Utili

GSK Issues $2.5 Billion Buyback, Raises Midterm Outlook After Beating Market Views -- Update

5 feb 2025, 07:43 UTC

Utili

GSK Expects Further Profit Growth After Beating Market Views

13 gen 2025, 07:14 UTC

Acquisizioni, Fusioni, Takeovers

GSK to Buy U.S. Rare Tumor Specialist IDRx for Up to $1.15 Billion

2 apr 2025, 09:27 UTC

Azioni calde

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

26 mar 2025, 22:29 UTC

Notizie principali

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- 2nd Update

26 mar 2025, 19:19 UTC

Notizie principali

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- Update

26 mar 2025, 17:39 UTC

Notizie principali

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- WSJ

19 mar 2025, 14:50 UTC

Notizie principali

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

17 mar 2025, 09:00 UTC

Notizie principali

Pfizer Has a New Playbook for Reviving Sales -- And It's Starting to Pay Off -- WSJ

24 feb 2025, 07:05 UTC

Acquisizioni, Fusioni, Takeovers

GSK Completes Acquisition of IDRx

14 feb 2025, 11:38 UTC

Notizie principali
Utili

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

14 feb 2025, 11:30 UTC

Notizie principali
Utili

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

5 feb 2025, 15:33 UTC

Discorsi di Mercato
Utili

GSK's Pipeline Has to Prove It Can Counter Concerns Over Vaccine Business -- Market Talk

5 feb 2025, 08:38 UTC

Discorsi di Mercato
Utili

GSK Needs to Show It Can Navigate Vaccines Challenge -- Market Talk

5 feb 2025, 07:05 UTC

Utili

GSK PLC Had Seen 2031 Sales Outlook at More Than GBP38B

5 feb 2025, 07:04 UTC

Utili

GSK PLC Sees 2031 Sales Outlook at More Than GBP40B

5 feb 2025, 07:03 UTC

Utili

GSK PLC Sees 2025 Adjusted EPS Growth of 6%-8%

5 feb 2025, 07:03 UTC

Utili

GSK PLC Raises Mid-Term View

5 feb 2025, 07:03 UTC

Utili

GSK PLC Sees 2025 Adjusted Operating Growth of 6% - 8%

5 feb 2025, 07:02 UTC

Utili

GSK PLC Sees 2025 Turnover Growth of 3% to 5%

5 feb 2025, 07:02 UTC

Utili

GSK PLC Issues GBP2B Buyback

5 feb 2025, 07:01 UTC

Utili

GSK PLC Declares 4Q Dividend of 16p

5 feb 2025, 07:00 UTC

Utili

GSK PLC 4Q Core EPS Consensus Was 20.6p

5 feb 2025, 07:00 UTC

Utili

GSK PLC 4Q Sales Consensus Was GBP7.83B

5 feb 2025, 07:00 UTC

Utili

GSK PLC 4Q Pretax Pft GBP563M

5 feb 2025, 07:00 UTC

Utili

GSK PLC 4Q EPS 10.0p

5 feb 2025, 07:00 UTC

Utili

GSK PLC 4Q Adj EPS 23.2p

5 feb 2025, 07:00 UTC

Utili

GSK PLC 4Q Oper Pft GBP696M

Confronto tra pari

Modifica del prezzo

GlaxoSmithKline PLC Previsione

Obiettivo di Prezzo

By TipRanks

11.15% in crescita

Previsioni per 12 mesi

Media 1,593.33 GBX  11.15%

Alto 2,290 GBX

Basso 1,450 GBX

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per GlaxoSmithKline PLC - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

12 ratings

2

Acquista

8

Mantieni

2

Vendi

Sentiment

By Acuity

139 / 386 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.